Show simple item record

dc.contributor.authorKaralis, T
dc.contributor.authorPoulogiannis, G
dc.coverage.spatialSwitzerland
dc.date.accessioned2024-07-03T12:44:46Z
dc.date.available2024-07-03T12:44:46Z
dc.date.issued2024-04-04
dc.identifierARTN 629
dc.identifiercells13070629
dc.identifier.citationCells, 2024, 13 (7), pp. 629 -en_US
dc.identifier.issn2073-4409
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/6285
dc.identifier.eissn2073-4409
dc.identifier.eissn2073-4409
dc.identifier.doi10.3390/cells13070629
dc.identifier.doi10.3390/cells13070629
dc.description.abstractLysophosphatidic acid (LPA) is a phospholipid that displays potent signalling activities that are regulated in both an autocrine and paracrine manner. It can be found both extra- and intracellularly, where it interacts with different receptors to activate signalling pathways that regulate a plethora of cellular processes, including mitosis, proliferation and migration. LPA metabolism is complex, and its biosynthesis and catabolism are under tight control to ensure proper LPA levels in the body. In cancer patient specimens, LPA levels are frequently higher compared to those of healthy individuals and often correlate with poor responses and more aggressive disease. Accordingly, LPA, through promoting cancer cell migration and invasion, enhances the metastasis and dissemination of tumour cells. In this review, we summarise the role of LPA in the regulation of critical aspects of tumour biology and further discuss the available pre-clinical and clinical evidence regarding the feasibility and efficacy of targeting LPA metabolism for effective anticancer therapy.
dc.formatElectronic
dc.format.extent629 -
dc.languageeng
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.relation.ispartofCells
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectcancer metabolism
dc.subjectlysophosphatidic acid
dc.subjectoncometabolite
dc.subjectphospholipid
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectSignal Transduction
dc.subjectCell Movement
dc.subjectLysophospholipids
dc.titleThe Emerging Role of LPA as an Oncometabolite.en_US
dc.typeJournal Article
dcterms.dateAccepted2024-04-01
dc.date.updated2024-07-03T12:44:16Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.3390/cells13070629en_US
rioxxterms.licenseref.startdate2024-04-04
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/38607068
pubs.issue7
pubs.organisational-groupICR
pubs.organisational-groupICR/Primary Group
pubs.organisational-groupICR/Primary Group/ICR Divisions
pubs.organisational-groupICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-groupICR/Primary Group/ICR Divisions/Cancer Biology/Signalling & Cancer Metabolism
pubs.publication-statusPublished online
pubs.publisher-urlhttp://dx.doi.org/10.3390/cells13070629
pubs.volume13
icr.researchteamSignalling Cancer Metaben_US
dc.contributor.icrauthorKaralis, Theodoros
dc.contributor.icrauthorPoulogiannis, Georgios
icr.provenanceDeposited by Mr Arek Surman on 2024-07-03. Deposit type is initial. No. of files: 1. Files: The Emerging Role of LPA as an Oncometabolite.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/